Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart TagsBone & JointCardiovascularCatDogEfficacyExotic PetNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Effect of PCSO-524 on OA Biomarkers and Weight Bearing Properties in Canine Shoulder and Coxofemeral Osteoarthritis
This trial included 66 mixed breed dogs with x-ray confirmed OA split into two treatment groups for 24 weeks. These were 1) PCSO-524 (5 mg/kg) and 2) fish oil (2,000 mg/d). The dogs were all placed on a standardised diet to minimise variability.
The results suggest that PCSO-524 is protective against cartilage breakdown in dogs with osteoarthritis.
Application of the Polyunsaturated fatty acid compound PCSO-524 in the post operative recovery of dogs that have had stifle surgery
World Small Animal Veterinary Assoc.
38th Annual Congress 6-9 March 2013, Auckland, New Zealand
The clinical outcomes of the use of PCSO-524 in 28 dogs that had undergone surgery on the stifle (which included correction of the patellar luxation and correction of cranial cruciate ligament rupture) were studied at the Small Animal Teaching Hospital, at Chulalongkorn University, Bangkok, Thailand.
Twenty-eight dogs that undergone both stifle surgery were included in our study. All test subjects had been given pre-emptive analgesia (morphine sulfate). NSAIDs and glucosamine had been administered before the surgery.
Two postoperative treatments were:
- NSAIDs treatment for one week in combination with glucosamine sulfate;
- only PCSO-524 treatments.
The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases
The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.
Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.
All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted